The hallmarks of successful anticancer immunotherapy

Lorenzo Galluzzi; Timothy A. Chan; Guido Guido Kroemer; Jedd D. Wolchok; Alejandro López‐Soto

doi:10.1126/scitranslmed.aat7807

Related publications

Article2018

Nanomaterials for modulating innate immune cells in cancer immunotherapy

Quoc‐Viet Le, Geon Yang, Yina Wu, Ho Won Jang, Mohammadreza Shokouhimehr, Yu‐Kyoung Oh

Article2024

Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

Nasim Ebrahimi, Al‐Hasnawi Rasool Riyadh Abdulwahid, Atena Mansouri, Nasrin Karimi, Rashid Jafardoust Bostani, Sheida Beiranvand, Samaneh Adelian, Roya Khorram, Reza Vafadar, Michael R Hamblin, Amir Reza Aref

Article2017

Trial watch: Dendritic cell-based anticancer immunotherapy

Abhishek D. Garg, Mónica Vara‐Pérez, Marco B.E. Schaaf, Patrizia Agostinis, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi

Article2022

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy

Jordan W. Conway, Jorja Braden, James S. Wilmott, Richard A Scolyer, Georgina V. Long, Inês Pires da Silva

Article2025

The dual role of chaperone-mediated autophagy in the response and resistance to cancer immunotherapy

Mohammadreza Saberiyan, Sarah Gholami, Mahsa Ejlalidiz, Mohammadsadegh Rezaeian Manshadi, Parisa Noorabadi, Michael R Hamblin